Fainting: Drugs That Cause or Treat It

Why Medications Cause Fainting

Syncope occurs when cerebral perfusion drops below the threshold needed to maintain consciousness. That threshold is roughly 35 mL per 100 g of brain tissue per minute. Medications can push perfusion below this line through three broad mechanisms: excessive vasodilation, volume depletion, or cardiac conduction disturbances.

Vasodilation and Venous Pooling

Alpha-1 blockers such as tamsulosin, doxazosin, and prazosin relax arterial and venous smooth muscle. The resulting venous pooling cuts cardiac preload, and standing up compounds the effect. A 2019 population-based cohort study in the BMJ found that alpha-blocker initiation was associated with a first-dose syncope incidence of 1.3 events per 100 person-years, with the highest risk in the first 14 days [4]. Nitrates (nitroglycerin, isosorbide mononitrate) and PDE-5 inhibitors (sildenafil, tadalafil) work through similar vasodilatory pathways. Combining a nitrate with a PDE-5 inhibitor can produce precipitous hypotension. This is not a rare interaction; the FDA black-box warning explicitly contraindicates the combination.

Volume Depletion

Loop diuretics (furosemide, bumetanide) and thiazides (hydrochlorothiazide, chlorthalidone) lower circulating volume directly. A patient who is already mildly dehydrated, common in older adults on fixed fluid intakes, can cross the syncope threshold after a single extra dose. The 2018 European Society of Cardiology (ESC) syncope guideline lists diuretics as a Class I recommendation to evaluate when investigating drug-induced orthostatic syncope [2].

QT Prolongation and Arrhythmia

Drugs that prolong the QT interval (antiarrhythmics like sotalol and amiodarone, certain antipsychotics like haloperidol, macrolide antibiotics like azithromycin) can trigger torsades de pointes, a polymorphic ventricular tachycardia. Torsades often presents as abrupt syncope without warning. The CredibleMeds database maintained by the Arizona Center for Education and Research on Therapeutics catalogues over 200 drugs with known, possible, or conditional QT-prolonging risk [5].

The Most Common Drug Classes Behind Syncope

The list is longer than most patients expect. Below are the major categories, organized by mechanism, along with representative agents.

Antihypertensives

ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), and calcium channel blockers (amlodipine, nifedipine) lower blood pressure by design. In the SPRINT trial (N=9,361), intensive blood pressure control (target systolic <120 mmHg) increased the rate of syncope to 3.5% vs. 2.4% in the standard-control arm [6]. That 1.1 percentage-point difference translates to roughly one extra syncope event per 91 patients treated to the intensive target.

Psychotropic Medications

Tricyclic antidepressants (amitriptyline, nortriptyline), SSRIs (sertraline, escitalopram), and antipsychotics (quetiapine, risperidone) contribute through multiple routes: orthostatic hypotension via alpha-1 blockade, QT prolongation, and serotonin-mediated bradycardia. A 2016 meta-analysis in the Journal of the American Geriatrics Society reported that SSRI use in older adults was associated with a 1.5-fold increase in fall-related syncope events [7].

Opioids and Sedatives

Morphine, oxycodone, and fentanyl induce histamine-mediated vasodilation and blunt the baroreflex. Benzodiazepines reduce sympathetic outflow. The combination is additive. Perioperative syncope in opioid-treated patients is common enough that the American Heart Association (AHA) 2017 scientific statement on syncope specifically flags opioid polypharmacy as a modifiable risk factor [8].

Dopaminergic Agents

Levodopa/carbidopa and dopamine agonists (pramipexole, ropinirole) used in Parkinson disease carry syncope rates between 5% and 12% in clinical trials, reflecting both the drug effect and the autonomic neuropathy inherent to the disease [9]. Dose titration over weeks, rather than days, reduces early orthostatic events.

How Clinicians Identify Drug-Induced Syncope

Diagnosis is largely one of pattern recognition and exclusion. No single test confirms that a specific drug caused a faint.

The Medication Timeline

The ESC guideline recommends building a detailed medication timeline. Did the patient start a new drug or increase a dose within the preceding four weeks? Was a second hypotensive agent added? A temporal link between drug change and first syncope episode is the strongest diagnostic clue. "The most effective diagnostic tool for drug-induced syncope is a careful medication history, not a tilt-table test," notes the ESC 2018 syncope guideline writing committee [2].

Orthostatic Vital Signs

A sustained systolic drop of 20 mmHg or more (or 30 mmHg in hypertensive patients) within three minutes of standing supports orthostatic hypotension. Active stand testing is preferred over tilt-table testing for initial evaluation. The sensitivity of bedside orthostatic vitals is roughly 40 to 60%, so a negative result does not rule out the diagnosis [10].

Electrocardiogram and Monitoring

A 12-lead ECG screens for QT prolongation, conduction disease, and Brugada pattern. Corrected QT (QTc) values exceeding 500 ms carry meaningful arrhythmic risk. For patients on QT-prolonging drugs, the AHA/ACC 2017 guideline on ventricular arrhythmias recommends serial ECG monitoring after drug initiation and with dose increases [11].

Drugs That Treat Recurrent Fainting

When the offending medication has been stopped or adjusted and syncope persists, pharmacotherapy targets the underlying mechanism. The evidence base is thinner than many patients assume. Only a few agents have randomized trial support.

Midodrine for Orthostatic Hypotension

Midodrine is an alpha-1 agonist that raises standing blood pressure by constricting arterioles and veins. The standard dose is 5 to 10 mg taken three times daily during waking hours (the last dose should be given at least four hours before bedtime to avoid supine hypertension). A randomized controlled trial published in JAMA (N=126) showed midodrine increased standing systolic blood pressure by a mean of 22 mmHg and reduced syncope-related symptoms by 42% compared to placebo [12]. The FDA approved midodrine in 1996 for symptomatic orthostatic hypotension. Supine hypertension is the primary adverse effect, occurring in roughly 25% of patients.

Fludrocortisone for Vasovagal Syncope

Fludrocortisone, a synthetic mineralocorticoid, expands plasma volume by promoting renal sodium retention. Typical dosing starts at 0.1 mg daily and may increase to 0.2 mg. The POST-5 trial (N=210) did not reach its primary endpoint for fludrocortisone in vasovagal syncope overall, but a prespecified subgroup of patients with low baseline blood pressure showed a 45% relative reduction in recurrence [13]. Hypokalemia and ankle edema are dose-limiting side effects that require monitoring.

Beta-Blockers in Select Populations

Beta-blockers were once dismissed for vasovagal syncope after the POST-1 trial showed no benefit. The POST-2 trial (N=128), published in Circulation in 2022, changed the conversation. Among patients aged 40 years and older, metoprolol (titrated to 100 to 200 mg daily) reduced the two-year syncope recurrence rate from 61% to 25%, a statistically significant 36 percentage-point absolute reduction [3]. For patients under 40, the benefit was absent. Dr. Robert Sheldon, the trial's lead investigator, stated: "Age appears to be a key modifier. Beta-blockers should not be used as a blanket treatment for vasovagal syncope, but in patients over 40 the data are now persuasive" [3].

Droxidopa for Neurogenic Orthostatic Hypotension

Droxidopa is a synthetic amino acid prodrug converted to norepinephrine. It is FDA-approved specifically for neurogenic orthostatic hypotension associated with Parkinson disease, multiple system atrophy, and pure autonomic failure. Dosing begins at 100 mg three times daily and may titrate to 600 mg three times daily. In a pooled analysis of three key trials (N=460), droxidopa improved standing systolic blood pressure by 8 to 11 mmHg and reduced dizziness and near-syncope scores by 1.5 points on a 10-point scale at one week [14]. The short-duration endpoint is a limitation; longer-term efficacy data remain mixed.

Non-Pharmacologic Measures as Adjuncts

Physical counterpressure maneuvers (leg crossing, hand gripping, squatting) can abort an impending vasovagal episode. The PC-Trial (N=223), published in Circulation, demonstrated a 39% relative reduction in syncope recurrence with counterpressure training alone [15]. Increased fluid intake (2 to 3 liters daily) and salt supplementation (6 to 9 g daily, unless contraindicated by heart failure or hypertension) remain first-line recommendations in every major guideline.

When Fainting Requires Emergency Evaluation

Not every faint needs an ER visit. But several patterns demand same-day cardiology assessment or emergency department evaluation.

High-Risk Features

Syncope during exertion, syncope preceded by palpitations, syncope with chest pain, and syncope in a patient with known structural heart disease all carry elevated risk for sudden cardiac death. The Canadian Syncope Risk Score, validated in over 5,000 emergency department visits, stratifies 30-day serious adverse event risk using seven variables: abnormal ECG, history of heart disease, elevated troponin, systolic blood pressure <90 mmHg or greater than 180 mmHg, and emergency department diagnosis of vasovagal or cardiac syncope [16].

When to Suspect a Drug Cause vs. A Cardiac Cause

Drug-induced syncope typically follows a predictable pattern: positional (standing from sitting), gradual onset with prodromal lightheadedness, and temporal relationship with medication changes. Cardiac syncope is often sudden, exertional, or associated with abnormal ECG findings. Overlap exists. A patient on sotalol who faints may be experiencing drug-induced QT prolongation, not benign orthostatic hypotension. The ECG is the differentiator.

Special Populations and Polypharmacy

Older Adults

Adults over 65 account for a disproportionate share of syncope hospitalizations. In this group, polypharmacy (five or more medications) is the rule, not the exception. A prospective cohort study in the Journal of the American Geriatrics Society (N=2,352) found that each additional antihypertensive agent increased the odds of recurrent syncope by 17% [17]. Deprescribing, the deliberate reduction of unnecessary medications, is the recommended first step in the ESC guideline before adding any syncope-preventive drug.

Patients on GLP-1 Receptor Agonists

Semaglutide and tirzepatide can reduce body weight and blood pressure simultaneously. Patients already taking antihypertensives may develop symptomatic orthostatic hypotension as they lose weight. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced a mean systolic blood pressure reduction of 6.2 mmHg at 68 weeks [18]. Clinicians should reassess antihypertensive doses at each GLP-1 dose escalation.

Pregnant Patients

Blood volume increases by roughly 40 to 50% during pregnancy, yet systemic vascular resistance drops. Syncope in the first and second trimesters is common. A cohort study in JACC (N=481,930) found syncope during pregnancy occurred in 1.04% of pregnancies, with the highest incidence in the first trimester [19]. Most pharmacologic syncope treatments (midodrine, fludrocortisone) lack safety data in pregnancy. Compression stockings and increased salt and fluid intake are the primary interventions.

A Practical Decision Framework

Step one: review every current medication for syncope potential. Step two: stop, reduce, or substitute the most likely offender. Step three: recheck orthostatic vitals after two weeks off the suspected drug. Step four: if syncope recurs despite medication adjustment, consider midodrine for orthostatic mechanisms or metoprolol for vasovagal mechanisms (in patients aged 40 and above). Step five: refer to cardiology or autonomic neurology if two or more drugs have been tried without benefit, or if ECG abnormalities are present.

Metoprolol 100 to 200 mg daily reduced two-year vasovagal syncope recurrence from 61% to 25% in the POST-2 trial, but only in patients aged 40 and older [3].